MX2021009232A - Metodos de tratamiento del dolor con un antihiperalgesico de tiazolina. - Google Patents

Metodos de tratamiento del dolor con un antihiperalgesico de tiazolina.

Info

Publication number
MX2021009232A
MX2021009232A MX2021009232A MX2021009232A MX2021009232A MX 2021009232 A MX2021009232 A MX 2021009232A MX 2021009232 A MX2021009232 A MX 2021009232A MX 2021009232 A MX2021009232 A MX 2021009232A MX 2021009232 A MX2021009232 A MX 2021009232A
Authority
MX
Mexico
Prior art keywords
methods
compound
hyperalgesic
thiazoline
treating pain
Prior art date
Application number
MX2021009232A
Other languages
English (en)
Inventor
Scott Dax
Original Assignee
Cersci Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cersci Therapeutics Inc filed Critical Cersci Therapeutics Inc
Publication of MX2021009232A publication Critical patent/MX2021009232A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan métodos para tratar el dolor neuropático diabético y el dolor posquirúrgico. Los métodos incluyen administrar a un individuo una cantidad terapéuticamente eficaz de un compuesto de Fórmula I (Compuesto 1). El método se puede usar para tratar la neuropatía diabética que surge de cualquier tipo de daño nervioso, y también se puede usar para tratar el dolor posquirúrgico que surge de cualquier procedimiento quirúrgico sin los efectos secundarios asociados con analgésicos ampliamente usados tales como los opioides. El Compuesto 1 se puede formular en muchas formas de dosificación adecuadas, incluidas formas de dosificación orales tales como comprimidos.
MX2021009232A 2019-02-01 2019-12-19 Metodos de tratamiento del dolor con un antihiperalgesico de tiazolina. MX2021009232A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962800232P 2019-02-01 2019-02-01
PCT/US2019/067454 WO2020159643A1 (en) 2019-02-01 2019-12-19 Methods of treating pain with a thiazoline anti-hyperalgesic

Publications (1)

Publication Number Publication Date
MX2021009232A true MX2021009232A (es) 2021-09-08

Family

ID=67211892

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009232A MX2021009232A (es) 2019-02-01 2019-12-19 Metodos de tratamiento del dolor con un antihiperalgesico de tiazolina.

Country Status (14)

Country Link
US (4) US20200246316A1 (es)
EP (1) EP3917520A1 (es)
JP (1) JP2022523499A (es)
KR (1) KR20210124311A (es)
CN (1) CN113365626A (es)
AU (1) AU2019427298A1 (es)
BR (1) BR112021015115A2 (es)
CA (1) CA3126802A1 (es)
EA (1) EA202191947A1 (es)
IL (1) IL284943A (es)
MX (1) MX2021009232A (es)
SG (1) SG11202107875SA (es)
WO (2) WO2020159565A1 (es)
ZA (1) ZA202104960B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220241200A1 (en) * 2021-01-29 2022-08-04 Insitu Biologics, Inc. Compositions and methods for sustained treatment of pain
WO2022266211A1 (en) * 2021-06-17 2022-12-22 Acadia Pharmaceuticals Inc. Methods of treating, ameliorating, and/or preventing osteoarthritic pain

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
AU668386B2 (en) 1992-03-25 1996-05-02 Depomed Systems, Incorporated Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
PT998271E (pt) 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
IL149421A0 (en) 1999-11-02 2002-11-10 Depomed Inc Pharmaceutical compositions containing fed mode inducing agents
AU767812B2 (en) 2000-02-04 2003-11-27 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
KR20040020056A (ko) 2001-05-29 2004-03-06 디포메드 디벨롭먼트 리미티드 위식도 역류 질환 및 야간 위산분비의 치료 방법
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
EP1438027A1 (en) 2001-10-25 2004-07-21 DepoMed, Inc. Methods of treatment using a gastric retained losartan dosage
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CN101272684A (zh) * 2005-07-26 2008-09-24 多夫药品公司 治疗神经病及相关病症的方法及组合物
CN101484152A (zh) * 2006-06-08 2009-07-15 舒沃茨药物股份公司 用于疼痛性医学病症的治疗组合
NL2003786C2 (en) * 2009-11-11 2010-07-30 Medner B V COMPOSITION FOR TOPICAL APPLICATION, USES THEREOF, APPLICATOR DEVICE AND KIT OF PARTS.
WO2011112602A1 (en) * 2010-03-10 2011-09-15 Galleon Pharmaceuticals, Inc. Analgesic compounds, compositions, and uses thereof
US10400264B2 (en) * 2016-12-01 2019-09-03 Promega Corporation 5,5-disubstituted luciferins and their use in luciferase-based assays

Also Published As

Publication number Publication date
SG11202107875SA (en) 2021-08-30
EP3917520A1 (en) 2021-12-08
US20200246318A1 (en) 2020-08-06
US20200246316A1 (en) 2020-08-06
WO2020159643A1 (en) 2020-08-06
IL284943A (en) 2021-09-30
WO2020159565A1 (en) 2020-08-06
ZA202104960B (en) 2023-12-20
CN113365626A (zh) 2021-09-07
BR112021015115A2 (pt) 2021-09-28
CA3126802A1 (en) 2020-08-06
JP2022523499A (ja) 2022-04-25
US20220168279A1 (en) 2022-06-02
EA202191947A1 (ru) 2021-11-03
US20200289474A1 (en) 2020-09-17
KR20210124311A (ko) 2021-10-14
AU2019427298A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
ZA202104960B (en) Methods of treating pain with a thiazoline anti-hyperalgesic
ZA202109010B (en) Compounds and methods for the treatment of covid-19
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
MX2023008453A (es) Metodos de tratamiento para el abuso de sustancias.
SG135193A1 (en) Dosing schedule for erbb2 anticancer agents
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2021015352A (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
PH12019500242A1 (en) 9-aminomethyl minocycline compounds and uses thereof
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
Trivedi et al. A meta-analysis comparing efficacy of continuous terbinafine with intermittent itraconazole for toenail onychomycosis
EA200970764A1 (ru) Способ лечения расстройств, вызванных пролиферацией клеток, с применением стимуляторов секреции гормона роста
MX2021007565A (es) Composiciones y metodos para la terapia contra el cancer.
WO2020005869A3 (en) Compositions and methods for the treatment of cancer characterized with pcsk9 expression
TW201129361A (en) Methods for treating pain
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
BR112022009794A2 (pt) Método para tratar câncer no pulmão
MX2021011469A (es) Combinacion de lisina(s) y antibiotico(s) para tratar o prevenir endocarditis infecciosa debida a bacterias gram-positivas.
EP4233842A3 (en) Avexitide for the treatment of hyperinsulinemic hypoglycemia
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.